We report here the beneficial effects of the GLP-1 agonist exenatide, which can be administered by intermittent subcutaneous injection, on glucose homeostasis, cardiac function and survival in a transgenic mouse model of dilated cardiomyopathy. The gene discussed is GLP1R; the disease is dilated cardiomyopathy.